Drug Trial Radar · NCT00137995
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
481
Actual
Start
Jun 2003
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Lymphoma Study AssociationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 30, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by the event free survival. The goal is to obtain a 15% increase of event free survival at 2 years.
Conditions
- Lymphoma, Large-Cell, Diffuse
Interventions
RituximabDrug
375 mg/m² D-2/D1
EtoposideDrug
100 mg/m² D1-D2-D3
CarboplatineDrug
max 800mg D2
Ifosfamide + MesnaDrug
5 g/m² from D2 to D13
CisplatineDrug
100 mg/m² from D1 to D13
Cytosine ArabinosideDrug
2000 mg/m²/12 h D2 D3
DexamethasoneDrug
40 mg From D1 to D4
Autologous Stem Cell TransplantationProcedure
BCNUDrug
300mg/m² on D-6
EtoposideDrug
200 mg/m² from D-6 to D-3
CytarabineDrug
100 mg/m² from D-6 to D-3
MelphalanDrug
140 mg/m² on D-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- MARR (mobilization adjusted response rate)Time frame: 3 months
- EFS (event free survival)Time frame: 2 years post transplantation
Locations
10 sites in 10 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Australian leukemia and lymphoma group
Sydney, Australia
Groupe d'atude des lymphome de l'adulte
Yvoir, Belgium
Czech Lymphoma study group
Prague, Czechia
Hospital district of south west Finland
Turku, Finland
German high grade non hodgkin's lymphoma group
Hamburg, Germany
Israel Society of Hematology
Tel HaShomer, Israel
Nordic center
Uppsala, Sweden
Schweirische Arbeitsgruppe fur klinische Krebsforschung
Lausanne, Switzerland
National cancer research institute
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.